Compounded semaglutide near me in 2026: where it's actually still available
Compounded semaglutide availability has dramatically narrowed in 2026. FDA proposed permanently ending 503B mass compounding April 30, 2026. Hims exited February 2026 amid Novo Nordisk lawsuit. State boards of pharmacy enforce at different paces. Here's the actual map of where compounded semaglutide is still findable, plus legitimate alternatives.
4 min readUpdated
- Apr 0 2026
- FDA proposed permanent end of 503B compounding
- Jun 0 2026
- FDA comment period close
- Feb 06
- Hims exited compounded GLP-1 market
- 0+
- FDA warning letters in 2026
Jump to section
What's actually happening to compounded semaglutide in 2026
The 2022-2024 FDA semaglutide shortage allowed 503B outsourcing facilities and 503A retail compounders to produce semaglutide at scale. Telehealth platforms — Hims, Sequence, Push Health, dozens of independents — sold compounded semaglutide at prices substantially below branded Wegovy.
That era is rapidly ending. Novo Nordisk declared the shortage resolved in late 2024. The FDA confirmed resolution a on April 30, 2026 proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list. Public comment closes June 29, 2026.
Hims and Hers exited the compounded GLP-1 market on February 7, 2026 amid regulatory pressure and a Novo Nordisk lawsuit. Sequence (Weight Watchers) and most major telehealth platforms followed.
Net result: compounded semaglutide is in active wind-down. State-by-state availability varies significantly.
State-by-state availability (general patterns)
California, New York, Illinois: state pharmacy boards actively enforcing FDA April 2026 guidance. Compounding pharmacies under significant pressure. Most large compounders have exited semaglutide; smaller 503A pharmacies may still compound on individual prescriptions for documented medical need only.
Texas, Florida, Georgia, Arizona: more permissive enforcement timeline. Some 503A retail compounding still occurring through independent pharmacies. Not the same scale as 2023-2024.
Massachusetts, Washington, Oregon: relatively strict enforcement environment. Compounded semaglutide largely unavailable through retail channels.
Generally: rural and southern states have somewhat more availability than coastal urban states. But this is changing rapidly — what's available in June 2026 may be gone by September 2026.
How to actually find compounded semaglutide (if pursuing this path)
Independent pharmacies that compound. Major chain pharmacies (CVS, Walgreens, Rite Aid) do not compound. You need a 503A retail compounding pharmacy. Use the PCAB (Pharmacy Compounding Accreditation Board) directory or search for 'compounding pharmacy near me.'
Telehealth platforms still in the market. Most major platforms have exited. A few independent telehealth services still prescribe compounded semaglutide as of mid-2026 — but legitimacy varies widely. Verify the prescribing physician is licensed in your state and the dispensing pharmacy is registered and accredited.
Red flags to avoid: 'No prescription needed' offers, prices below $100/month, foreign-pharmacy mail-order, no physical pharmacy address, no licensed clinician involvement.
Quality concerns: compounded drugs don't undergo FDA review for safety, efficacy, or manufacturing quality. Recent FDA warning letters cite dosing errors, contamination, and mislabeling. Even legitimate compounders vary in quality control.
Legitimate branded alternatives
Foundayo (orforglipron) via LillyDirect at $149-299/month by dose. Daily oral pill, FDA-approved April 1, 2026 for chronic weight management. Different molecule than semaglutide, with lower average weight loss (11.2% at 72 weeks on the top dose).
Zepbound vials via LillyDirect at $299-449/month when refilled within 45 days. Same molecule (tirzepatide) as injectable Zepbound pens, but vials are substantially cheaper. Better efficacy than semaglutide (~22% vs ~15% weight loss).
NovoCare Wegovy self-pay at $349/month ($199/month for the first two fills of 0.25 mg and 0.5 mg for new patients through December 31, 2026). The Wegovy pill is $149-299/month by dose.
Insurance appeal. Many self-pay patients have insurance that initially denied. No carrier publishes appeal success rates, but well-documented appeals routinely succeed. Worth attempting before moving to compounded path.
What happens if you're currently on compounded
Don't panic. Compounded supply is winding down but not instantly gone. You have time to plan a transition.
Talk to your prescriber soon. They can document your current dose, response, and medical history to make insurance appeals or brand-name PA easier.
Plan a transition path. Options: switch to Foundayo (orforglipron) at $149-299/mo (different molecule, lower average weight loss), Zepbound LillyDirect vials at $299-449/mo (higher average weight loss), or branded Wegovy through insurance or NovoCare at $349/mo.
Don't suddenly stop. Discontinuation without a plan typically causes rapid weight regain (50-70% of lost weight within 12 months on average). Bridge to another GLP-1 option ideally.
What to do if no legitimate path works
Insurance appeal with full documentation. Use our appeal letter generator. Multiple appeal levels available. No carrier publishes success rates, but well-documented appeals routinely succeed.
Direct request to manufacturer patient assistance program (PAP). NovoCare and LillyDirect PAPs exist for patients with documented inability to pay. Application required.
Ask about the pills. Foundayo (orforglipron) and the Wegovy pill both start at $149/month self-pay, rising by dose to $299/month.
Lifestyle-only plus monitoring if no medication path is affordable. Not ideal, but maintainable with structured support. Some patients use this temporarily before insurance coverage becomes available.
Sources
Primary sources cited above. FDA labeling, peer-reviewed trials, and specialty-society guidelines only.
- FDA Proposal to Remove Semaglutide and Tirzepatide from 503B Bulk-Compounding List · U.S. Food and Drug Administration, 2026
- Hims & Hers Exits Compounded GLP-1 Market · Press release / industry coverage, 2026
- FDA Warning Letters Issued to Compounding Pharmacies · U.S. Food and Drug Administration, 2026
People also ask
Where can I get compounded semaglutide near me in 2026?
Availability has dramatically narrowed. Major telehealth platforms (Hims, Sequence) exited compounded GLP-1 in early 2026. Some independent 503A retail compounding pharmacies still produce semaglutide for individual prescriptions in some states (more in TX/FL/AZ than in CA/NY/IL). The FDA proposed permanently ending mass compounding April 30, 2026. Don't build a long-term plan around compounded supply.
Is compounded semaglutide legal in 2026?
In a narrowing legal grey zone. 503B mass compounding is proposed to end permanently (FDA April 30, 2026 proposal, public comment closes June 29, 2026). Individual 503A retail compounding for documented medical need may continue. Compounded semaglutide bought from foreign mail-order pharmacies or 'no prescription' sites is illegal and dangerous.
Why did Hims stop selling compounded semaglutide?
Hims exited February 7, 2026 amid Novo Nordisk lawsuit pressure and FDA enforcement signaling. Most major telehealth platforms followed. The combination of (a) shortage officially resolved by Novo, (b) FDA escalating enforcement, and (c) brand lawsuit risk made compounded GLP-1 too risky for publicly-traded telehealth companies to continue.
What's the cheapest legitimate alternative to compounded semaglutide?
The lowest branded self-pay prices start at $149/month: Foundayo (orforglipron) via LillyDirect and the Wegovy pill via NovoCare Pharmacy, each $149-299/month by dose. Foundayo was FDA-approved April 1, 2026 for chronic weight management and is taken with or without food. It is a different molecule than semaglutide (non-peptide vs peptide), with 11.2% average weight loss at 72 weeks on the top dose in ATTAIN-1.
Will compounded semaglutide come back if the FDA rule doesn't pass?
Possibly, but expect ongoing regulatory pressure even if the specific April 2026 rule doesn't finalize. Novo Nordisk's lawsuits against compounders continue. The legal grey zone narrows incrementally regardless of any single FDA decision. Don't build a treatment plan assuming compounded will remain widely available long-term.
Related reads
Compounded GLP-1 availability in 2026: who's still shipping, who's stopped
On April 30, 2026 the FDA proposed permanently ending mass compounding of semaglutide and tirzepatide, issued 30 warning letters, and opened a comment period through June 29. Hims already exited. Here's who's still operating and what to do.
Compounded GLP-1 in 2026: the complete legal map (post-503B rule)
What 'compounded' actually means, where the law stands after the April 2026 FDA rule, what's still legitimate, what isn't, and how to read a program's compliance posture in 10 minutes.
Wegovy cost without insurance in 2026: cheapest legitimate paths
Wegovy's pharmacy list price is ~$1,349 per month. For uninsured patients, the cheapest legitimate paths in 2026 are NovoCare self-pay at $349/month, the Wegovy pill at $149-299/month, or a switch to Foundayo (orforglipron) at $149-299/month when your prescriber agrees. Compounded semaglutide is a narrowing legal grey zone. Here are the actual options and what's changing.